CAMBRIDGE, Mass. & SEATTLE--(

马萨诸塞州剑桥和西雅图--(

BUSINESS WIRE

商业热线

)--Exigent Research and ConcertAI announced a major multi-year partnership to assure potentially lifesaving clinical trials are available to the broadest population of patients possible, combining the growing Exigent community oncology research network with a full suite of ConcertAI technologies providing study feasibility, patient-to-trial matching, and AI-powered study automations..

)--Exigent Research和ConcertAI宣布了一项重要的多年合作伙伴关系，以确保尽可能广泛的患者可以获得潜在的挽救生命的临床试验，将不断增长的Exigent社区肿瘤学研究网络与全套ConcertAI技术相结合，提供研究可行性，患者对试验的匹配以及AI支持的研究自动化。。

The technology suite will be tailored and fully integrated to all Exigent sites and all EMRs and powered by the CARAai™ platform. In June of 2024, ConcertAI

该技术套件将定制并完全集成到所有紧急站点和所有EMR，并由CARAai™平台提供支持。2024年6月，协奏曲

announced a collaboration with NVIDIA

宣布与NVIDIA合作

to advance technologies optimized for oncology clinical development, leveraging

推进针对肿瘤学临床开发优化的技术，利用

NVIDIA NIM

NVIDIA 名称

microservices, part of the

微服务，是

NVIDIA AI Enterprise

NVIDIA人工智能企业版

software platform for developing and deploying production-grade, end-to-end agentic AI pipelines. The approach allows for critical unstructured data to be processed adjacent to electronic medical records (EMRs) in near real time by a series of large language models (LLMs) and agentic AI solutions to help ensure the latest patient information is available to site research teams. .

用于开发和部署生产级端到端代理AI管道的软件平台。该方法允许通过一系列大型语言模型（LLM）和代理AI解决方案在电子病历（EMR）附近近实时处理关键的非结构化数据，以帮助确保现场研究团队可以获得最新的患者信息。。

“Oncology trials are complex, involving 40, 50, sometimes 70 levels of inclusion and exclusion criteria, many associated with evidence of disease progression and specific biomarker statuses,” said Jeff Elton, PhD, CEO of ConcertAI.  “Assessing these data requires highly skilled healthcare professionals accessing multiple documents and tabs in the EMR, often requiring one to four hours per patient.

。“评估这些数据需要高技能的医疗保健专业人员访问电子病历中的多个文档和选项卡，通常每位患者需要一到四个小时。

The latest series of vision LLMs and .

最新系列的vision LLM和。

NIM

尼姆

-

-（笑声）

deployed LLMs

已部署LLM

, with agentic AI, allow technology to augment the clinical research team with 4x productivity and no loss of precision – a true breakthrough in the model for biomedical research.”

通过代理人工智能，技术可以使临床研究团队的生产力提高4倍，并且不损失精度，这是生物医学研究模型的真正突破。”

Exigent was formed by the community oncology network, ONCare, just over four years ago. It was founded on the premise that patients in all community settings need access to a broad set of clinical trials to ensure they have the opportunity to realize the best possible clinical outcomes. The expertise and infrastructure available at the community level has increasingly converged towards that which was once only available at large academic medical centers..

Exigent是由社区肿瘤学网络ONCare在四年多前成立的。它的前提是，所有社区环境中的患者都需要获得广泛的临床试验，以确保他们有机会实现最佳的临床结果。社区层面上可用的专业知识和基础设施越来越趋向于以前只有大型学术医疗中心才能获得的专业知识和基础设施。。

“When we established Exigent, we knew there was a gap in clinical research access that assured that trial populations looked like the standard of care populations who would receive newly approved medicines,” said Sibel Blay, MD CEO of Exigent and co-founder of ONCare. “Exigent is a new approach that immediately catalyzed community site and clinical trials sponsors alike.

“当我们建立Exigent时，我们知道在临床研究方面存在差距，这确保了试验人群看起来像是接受新批准药物的标准护理人群，”Exigent首席执行官兼ONCare联合创始人Sibel Blay说。“Exigent是一种新方法，可以立即催化社区网站和临床试验赞助商。

We now offer one of the largest portfolios of clinical trials of any network organization in the U.S.” .

我们现在提供美国任何网络组织中最大的临床试验组合之一”。

In 2020, ConcertAI and ONCare incubated technologies in a novel joint research agreement. These have progressed to being some of the most broadly deployed AI-powered solutions in oncology research. The new generation being deployed as part of this partnership have the ability to access and process all data types, document types, and EMR sources in real time both for patient-to-trial matching and full-trial automation.

2020年，ConcertAI和ONCare在一项新的联合研究协议中孵化了技术。这些已经发展成为肿瘤学研究中部署最广泛的人工智能解决方案。作为该合作伙伴关系的一部分部署的新一代能够实时访问和处理所有数据类型，文档类型和EMR源，以进行患者到试验的匹配和全面的试验自动化。

The two areas have a defined roadmap of new capabilities for the partnership, including theranostics, CAR-T, and other novel therapies.  .

这两个领域有一个明确的合作伙伴关系新能力路线图，包括治疗学，CAR-T和其他新疗法。。

Financial terms of the partnership were not disclosed.

合伙企业的财务条款没有披露。

About ONCare

关于ONCare

ONCare Alliance is a community oncology network with 32 practices and 472 providers. Its mission is to empower independent practices, enhance community care, and foster innovation through a vast proprietary data engine and a network of exceptional oncological practices. ONCare is redefining excellence in cancer care, emphasizing agility, independence, and a comprehensive support system for clinical trials, advocacy, education, and training, all while maintaining a commitment to high-quality, accessible care for those affected by cancer.

ONCare联盟是一个社区肿瘤学网络，有32个实践和472个提供者。它的使命是通过一个庞大的专有数据引擎和一个特殊的肿瘤学实践网络，增强独立实践的能力，加强社区护理，并促进创新。ONCare正在重新定义卓越的癌症护理，强调灵活性、独立性以及临床试验、宣传、教育和培训的综合支持系统，同时致力于为癌症患者提供高质量、可获得的护理。

Founded in February 2024 with the merger of NCCA and QCCA, it is led by industry visionaries Dr. Sibel Blau, co-chair, president and CEO of ONCare Alliance (former president and CEO of QCCA), and Dr. Barbara McAneny, co-chair and chief officer of advocacy and government affairs for the ONCare Alliance (former founder and board chair of NCCA).

成立于2024年2月，由NCCA和QCCA合并而成，由行业远见者、ONCare联盟联合主席、总裁兼首席执行官Sibel Blau博士（QCCA前总裁兼首席执行官）和ONCare联盟联合主席兼倡导和政府事务首席官Barbara McAney博士（NCCA前创始人兼董事会主席）领导。

More About ONCare Alliance: .

有关ONCare联盟的更多信息：。

https://www.oncarealliance.com/

https://www.oncarealliance.com/

.

.

About ConcertAI

关于ConcertAI

ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies.

ConcertAI是医疗保健和生命科学领域预测性和生成性AI SaaS以及现实世界数据研究解决方案的领导者。我们的使命是通过研究就绪的数据、CARAai™技术和科学专业知识，与46多位领先的生物医学创新者、2000多家医疗保健提供者和医学会合作，加速患者的见识和成果。

TeraRecon.

TeraRecon。

®

®

provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ

为MRI和CT提供先进的放射学图像可视化和临床AI决策增强解决方案

®

®

is an Initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified

是ConcertAI的一项举措，为肿瘤学提供者提供ASCO对齐的自动QOPI和ASCO认证

®

®

quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, MA, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at

。协奏会总部位于马萨诸塞州剑桥市，在班加罗尔、法兰克福、费城、罗利达勒姆和东京设有办事处。有关更多信息，请访问

concertai.com

concertai.com网站

.

.